Project Grant R21HD120767
Award Date 8/20/26
Completion Date 7/31/28
Dollars Obligated $454K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $485,925 to the University of Massachusetts Boston to develop novel antioxidant compounds for treating preeclampsia, a life-threatening pregnancy complication. The primary goal is to design and synthesize cationic hydrazone antioxidants that can target mitochondria to reduce oxidative stress, improve...
- This Project Grant award from the Department of Health and Human Services National Institutes of Health National Institute of Child Health and Human Development provides $769,916 to Emergent Biotechnologies LLC for research into a novel therapy for preeclampsia. The funding supports Phase 1 of developing and characterizing a handle region peptide as an innovative treatment for preeclampsia under the Child Health and Human Development Extramural Research program (CFDA 93.865). Phase 1 work will...
- The National Institute of Child Health and Human Development, an office of the Department of Health and Human Services, awarded $600,016 to the University of California, San Diego on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate extracellular vesicles as mediators of kidney damage in preeclampsia. The research employs a three-dimensional microfluidic human proximal tubule kidney-on-a-chip model to study how placental and serum...
- The National Institute of Child Health and Human Development awarded $568,925 to the Board of Regents of the University of Nebraska on September 1, 2026, to conduct pharmacokinetic, pharmacodynamic, safety, and efficacy studies of targeted nanoparticle drug delivery to the placenta under CFDA 93.865 (Child Health and Human Development Extramural Research). The research addresses placental dysfunction, the underlying cause of preeclampsia, intrauterine growth restriction, and stillbirth, which...
- The National Institute of Child Health and Human Development awarded Emory University $426,948 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and validate artificial intelligence models that integrate electronic health record data to identify clinically meaningful subtypes of hypertensive disorders of pregnancy and predict disease onset before clinical diagnosis. The project will model longitudinal physiological changes and...
- The National Institute of Child Health and Human Development awarded Brigham & Women's Hospital Inc. $846,324 on August 19, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct epidemiologic research on antiseizure medication (ASM) safety during pregnancy and paternal exposure. The project applies advanced causal inference methods to two large U.S. healthcare databases—Medicaid and MarketScan, comprising over 50 million pregnancies—to...
- The National Institute of Child Health and Human Development awarded Brigham & Women's Hospital Inc. $485,930 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop a colorimetric vaginal insert device for early detection of premature rupture of membranes (PROM) and preterm PROM (PPROM). The device uses a pH-sensitive polymer that reacts to amniotic fluid by releasing a biocompatible dye, producing a visible color change in...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $3,330,084 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, for a project grant investigating causal links between the maternal plasma proteome, preeclampsia, and future cardiovascular disease. The research leverages proteomic analysis of circulating microparticles isolated from maternal plasma samples collected across first, second, and...
- The National Institute of Child Health and Human Development awarded Rowan University $408,380 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop hypoxia-responsive lipid nanoparticles for delivery of placental growth factor messenger RNA and soluble FMS-like tyrosine kinase-1 small interfering RNA to treat preeclampsia. The research addresses preeclampsia through targeted drug delivery to diseased placental tissue. The project...
- The National Institute of Child Health and Human Development, part of the Department of Health and Human Services National Institutes of Health, awarded $456,500 to The University of Texas Southwestern Medical Center on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award funds molecular characterization of human pregnancy-induced cervical epithelium through two research aims. First, the recipient will apply single-cell and spatial...